G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 26.2 PLN 4.8% Market Closed
Market Cap: 34.6m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genomed SA
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Accrued Liabilities
zł143.5k
CAGR 3-Years
-10%
CAGR 5-Years
24%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Accrued Liabilities
zł3.1m
CAGR 3-Years
-12%
CAGR 5-Years
26%
CAGR 10-Years
41%
R
Read Gene SA
WSE:RDG
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Accrued Liabilities
zł37.5m
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
8%
U
Urteste SA
WSE:URT
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Accrued Liabilities
zł7m
CAGR 3-Years
27%
CAGR 5-Years
20%
CAGR 10-Years
26%
No Stocks Found

Genomed SA
Glance View

Market Cap
34.6m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Overvaluation 3%
Intrinsic Value
Price
G

See Also

What is Genomed SA's Accrued Liabilities?
Accrued Liabilities
143.5k PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Accrued Liabilities amounts to 143.5k PLN.

What is Genomed SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
24%

Over the last year, the Accrued Liabilities growth was -30%. The average annual Accrued Liabilities growth rates for Genomed SA have been -10% over the past three years , 24% over the past five years .

Back to Top